(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 January 2019 (10.01.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/008484 A1

(51) International Patent Classification:
A61K 31/496 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/IB2018/054841

(22) International Filing Date:
29 June 2018 (29.06.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
201741023375 03 July 2017 (03.07.2017) IN

(71) Applicant: **SUVEN LIFE SCIENCES LIMITED** [IN/IN]; Serene Chambers, Road-5, Avenue – 7, Banjara Hills, Hyderabad-Telangana 500034 (IN).

(72) Inventors: **NIROGI, Ramakrishna**; Suven Life Sciences Limited, Serene Chambers, Road – 5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN). **GRANDHI, Venkata Ramalingayya**; Suven Life Sciences Limited, Serene Chambers, Road – 5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN). **JAYARAJAN, Pradeep**; Suven Life Sciences Limited, Serene Chambers, Road – 5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN). **JASTI, Venkateswarlu**; Suven Life Sciences Limited, Serene Chambers, Road – 5, Avenue – 7, Banjara Hills, Hyderabad, Telangana 500034 (IN).

(74) Agent: **MAHLA, Aaysu** et al.; Subramaniam & Associates, 7th Floor, M3M Cosmopolitan, Sector 66, Golf Course Extension Road, Gurugram, National Capital Region 122001 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2019/008484 A1

(54) **Title:** NEW USES OF A PURE 5-HT $_6$ RECEPTOR ANTAGONIST

(57) **Abstract:** The present invention relates to new uses of a pure 5-HT6 receptor antagonist, specifically 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, vascular dementia, chemotherapy-induced cognitive impairment and behavioral changes in dementia such as agitation, aggression, depression, anxiety, psychosis, disinhibition, or sleep disturbances. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.